AMB-FUBINACA (also known as FUB-AMB and MMB-FUBINACA [3]) is an indazole-based synthetic cannabinoid that is a potent agonist for the cannabinoid receptors, with K i values of 10.04 nM at CB 1 and 0.786 nM at CB 2 and EC 50 values of 0.5433 nM at CB 1 and 0.1278 nM at CB 2, [4] and has been sold online as a designer drug.

ADB-FUBINACA and AMB-FUBINACA are two synthetic indazole-derived cannabinoid receptor agonists, up to 140- and 85-fold more potent, respectively, than trans -∆ 9 -tetrahydrocannabinol (∆ 9 -THC), the main psychoactive compound of cannabis.

This substance is included in Schedule II of the 1971 Convention on Psychotropic Substances.

FUB-AMB, an indazole carboxamide synthetic cannabinoid recreational drug, was one of the compounds most frequently reported to governmental agencies worldwide between 2016 and 2019. It has been implicated in intoxications and fatalities, posing a risk to public health. In the current study, FUB-AMB …

AB-FUBINACA (AMB-FUBINACA [2]) is a psychoactive drug that acts as a potent agonist for the cannabinoid receptors, with K i values of 0.9 nM at CB 1 and 23.2 nM at CB 2 and EC 50 values of 1.8 nM at CB 1 and 3.2 nM at CB 2.

FUB-AMB can be differentiated from its ortho and meta fluoro positional isomers 1 and 2 based on the splitting pattern of the proton signals for the phenyl ring. For FUB-AMB, the fluoro substituent is in the para position and the molecule is sym-metrical at the phenyl ring due to the free rotation of the C2′-C3′ bond.

2017年1月19日 · AMB-FUBINACA is an example of the emerging class of “ultrapotent” synthetic cannabinoids and poses a public health concern. Collaboration among clinical laboratory staff, health professionals,...

2015年11月13日 · FUB-AMB is an analogue of AB-FUBINACA, a potent synthetic cannabinoid first synthesized by Pfizer. AB-FUBINACA exhibits a strong affinity (Ki =0.9 nM) for the CB1 receptor 1. The primary amide moiety in the L-valinamide side chain in AB-FUBINACA is replaced with a methyl ester in FUB-AMB.

acute administration of FUB-AMB has the potential to produce severe adverse reactions in humans up to, and including, death. The most predominant symptom in a cluster of confirmed FUB-AMB overdose cases in New York City in July 2016 was severe CNS depression, resulting in

On November 3, 2017, DEA published an order in the Federal Register amending 21 CFR 1308.11 (h) to temporarily place methyl 2- (1- (4-fluorobenzyl)-1 H -indazole-3-carboxamido)-3-methylbutanoate (other names: FUB-AMB, MMB-FUBINACA, AMB-FUBINACA) in schedule I of the CSA pursuant to the temporary scheduling provisions of 21 U.S.C. 811 (h). 82 FR ...